Psychiatr. pro Praxi, 2004; 3: 150-153

Léčba hyperkinetických poruch v současné praxi

prof. MUDr. Ivana Drtílková CSc, MUDr. Pavel Theiner Ph.D
Psychiatrická klinika LF MU a FN Brno

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drtílková I, Theiner P. Léčba hyperkinetických poruch v současné praxi. Psychiatr. praxi. 2004;9(3):150-153.

U náhodně vybraného vzorku 110 dětí a adolescentů ve věku od 4 do 16 let z jihomoravského regionu, které byly v průběhu posledních 2 let léčeny pro hyperkinetické poruchy v ambulantních a lůžkových psychiatrických zařízeních, jsme vyhodnotili sortiment používaných preparátů. Přestože v kontrolovaných studiích bylo prokázáno, že stimulancia a některá antidepresiva s převažujícím noradrenergním účinkem, patří k nejúčinnějším preparátům v této indikaci (preparáty první volby podle současných algoritmů léčby), výsledky našeho průzkumu ukazují, že téměř 70% pacientů bylo léčeno neuroleptiky, zejména risperidonem. Jsou diskutovány možné příčiny a uváděny indikace risperidonu u hyperkinetických poruch chování.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. 3. American psychiatric association. Diagnostic and Statistic Manual of Mental Disorders, 4rd Edition (DSM-IV). Washington, DC: American Psychiatric Association, 1994.
    2. 2. Mezinárodní klasifikace nemocí. 10. revize. Duševní poruchy a poruchy chování. Diagnostická kriteria pro výzkum. Praha: Psychiatrické centrum, 1996, 179 s.
    3. Bymaster F, Jason M, Katner B. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat. A potential mechanism for efficacy in AD/HD. Neuropsychopharmacology 2002; (27), 5: 700-710. Go to original source... Go to PubMed...
    4. Clinical practice guideline: treatment of the school-aged child with attention deficit/ hyperactivity disorder. Pediatrics 2001; 108: 1033-1044. Go to original source... Go to PubMed...
    5. Connor DE, Glatt MD, Lopez ID. Psychopharmacology and agression. A meta-analysis of stimulant effects on overt/covert agression-related behavior s in ADHD. J. Am. Acad. Child Adol. Psychiatry 2002; 41 (3): 253-258. Go to original source... Go to PubMed...
    6. Conners CK, Sitarenios G, Parker J. The revised Connors parent rating scale (CPRS-R): Factor structure, reliability and criterion validity. J of Abnormal Child Psychology 1998; 26: 279-291. Go to original source... Go to PubMed...
    7. Conners CK, Sitarenios G, Parker J. Revision and restandardisation of the Connors teacher rating scale (CPRS-R): Factor structure, reliability and criterion validity. Journal of Abnormal Child Psychology 1998; 26: 279-291. Go to original source... Go to PubMed...
    8. Drtílková I. Algoritmy léčby ADHD a komorbidních poruch. Psychiatrie 2003; 7 (suppl. 1): 16-17.
    9. Kratochvil Ch, Heiligenstein J, Dittman R. Atomoxetine and methylphenidate treatment in children with ADHD. A prospective, randomised, open-label study. J.Am.Acad Child Adolescent Psychiatry 2002; (41) 7: 776-784. Go to original source... Go to PubMed...
    10. Kutcher S, Aman M, et al. International consensus statement on ADHD and disruptive behaviour disorders.: Clinical implications and treatment practice suggestions. European Neuropsychopharmacology 2004; 14: 11-28. Go to original source... Go to PubMed...
    11. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with AD/HD. A randomised, placebo-controlled, dose. Response study. Pediatrics 2001; (108) 5: 1-9. Go to original source... Go to PubMed...
    12. Pliszka SR, Greenhill L, et al. The Texas childrens medication algorithm project: report of the Texas consensus conference panel on medication treatment of ADHD. J Am Acad Adolesc Psychiatry 2000; 39 (7): 908-919. Go to original source... Go to PubMed...
    13. The Maudsley Prescribing Guidelines 2003, 7th Edition, London and New York, Martin Dunitz, 2003.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.